| Literature DB >> 35145922 |
Min Wen1,2,3, Xiqiang Dang1,2, Shipin Feng4, Qingnan He1,2,3, Xiaoyan Li1,2, Taohua Liu3, Xiaojie He1,2.
Abstract
Recent studies have shown that intestinal microbes and metabolites are involved in the pathogenesis of many diseases. However, whether and how they are related to Henoch-Schönlein purpura (HSP) has yet to be understood. This work is designed to detect gut microbes, intestinal and serum metabolites in children with HSP, trying to discover the etiology and pathogenesis of HSP. A total of 86 children were recruited in this study, namely, 58 children with HSP (HSP group) and 28 healthy children as control groups (CON group). 16S rDNA amplicon sequencing technology and UPLC-QTOF/MS non-targeted metabolomics analysis were used to detect the intestinal microbes and metabolites, and also multi-reaction monitoring technology for detecting serum arachidonic acid (AA) and its metabolites. Then, correlation analysis was performed to explore the possible interaction between the differential gut microbes and metabolites. As a result, at the microbiota family level, the CON group had an advantage of Coriobacteriaceae while the HSP group had a dominant Bacteroidaceae. Five kinds of bacteria in the HSP group were significantly enriched at the genus level, and seven kinds of bacteria were significantly enriched in the CON group. A total of 59 kinds of gut metabolites significantly differ between the two groups, in which most are lipids and peptides. Spearman correlation analysis showed that Bacteroides, Dialister, and Agathobacter were associated with unsaturated fatty acids, especially AA metabolism. Then, we tested the AA related metabolites in serum and found thromboxane B2, leukotriene B4, prostaglandin D2, 9S-hydroxyoctadecadienoic acid, and 13S-hydroxyoctadecadienoic acid significantly changed. In conclusion, children with HSP had dominant Bacteroidaceae and decreased Coriobacteriaceae in the family level of gut microbes, and also lipids and peptides changed most in the gut metabolites. Our data suggested that the biosynthesis and metabolism of unsaturated fatty acids, especially AA and its metabolites, might participate in the occurrence and development of HSP.Entities:
Keywords: 16S rDNA; Arachidonic acid; Henoch-Schönlein purpura; gut microbiota; host metabolome; unsaturated fatty acid
Mesh:
Year: 2022 PMID: 35145922 PMCID: PMC8821812 DOI: 10.3389/fcimb.2021.796410
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Intestinal dysbiosis between HSP group and control group. (A) Venn diagram of OTU distribution in HSP group and control group. (B) PCoA analysis between HSP group and control group. (C) Histogram of the distribution of intestinal flora in the HSP group and control group at the phylum level. (D) LDA evolutionary branch diagram by LEfSe analysis. (E) Intestinal flora LEfSe analysis diagram (LDA >2, p < 0.05). (F) KEGG function prediction of intestinal microbes in two groups.
Figure 2Differences in intestinal flora among the subgroups of HSP and healthy group. (A) Intestinal flora LEfSe analysis diagram between the untreated group (UG) and control group (CON). (B) Intestinal flora LEfSe analysis diagram between the regular treated group (RG) and control group (CON). (C) Intestinal flora LEfSe analysis diagram between the withdrawal group (WG) and control group (CON). (D) Intestinal flora LEfSe analysis diagram between the no renal damage group (NO-RD) and control group (CON). (E) Intestinal flora LEfSe analysis diagram between the renal damage group (RD) and control group (CON). (F) Intestinal flora LEfSe analysis diagram between the no renal damage group (NO-RD) and renal damage group (RD). All LDA >2, p < 0.05.
Significantly different metabolites between HSP group and healthy control group.
| class | adduct | Metabolites | VIP | FC | p-value | m/z | rt(s) |
|---|---|---|---|---|---|---|---|
| Lipids | (M−H)− | 13(S)-Hydroxyoctadecadienoic acid | 1.807 | 0.614 | 0.046 | 295.228 | 93.236 |
| Lipids | (M+H−H2O)+ | 1-Palmitoylglycerol | 5.704 | 0.084 | 0.004 | 313.273 | 63.788 |
| Lipids | (M+H)+ | all cis- (6,9,12)-Linolenic acid | 1.846 | 0.509 | 0 | 279.231 | 91.423 |
| Lipids | (M+NH4)+ | Alpha-Linolenic acid | 1.266 | 0.303 | 0 | 296.265 | 64.367 |
| Lipids | (M+H)+ | Arachidonic Acid | 1.685 | 0.439 | 0 | 305.247 | 89.608 |
| Lipids | (M+CH3COO+2H)+ | cis-9-Palmitoleic acid | 2.043 | 0.484 | 0.001 | 315.252 | 157.651 |
| Lipids | (M+H)+/(M−H)− | Daidzein | 2.251 | 0.361 | 0.012 | 255.064 | 89.115 |
| Lipids | (M−H)− | Dodecanoic acid | 3.648 | 0.199 | 0.025 | 199.17 | 93.132 |
| Lipids | (M+H)+ | Geranylgeraniol | 1.564 | 0.417 | 0.005 | 291.267 | 68.07 |
| Lipids | (M+NH4)+ | Linoleic acid | 2.216 | 0.634 | 0.025 | 298.274 | 84.196 |
| Lipids | (M+H−H2O)+ | Oleic acid | 1.437 | 0.374 | 0.003 | 265.252 | 67.42 |
| Lipids | (M+H)+ | Eicosapentaenoic acid | 6.146 | 0.408 | 0.009 | 303.231 | 65.731 |
| Lipids | (M+H)+ | Formononetin | 1.119 | 4.606 | 0.048 | 269.08 | 75.902 |
| Lipids | (2M+H)+ | L-Norleucine | 1.715 | 2.934 | 0.003 | 263.196 | 493.524 |
| Peptides | (2M+H)+ | DL-Phenylalanine | 1.129 | 2.019 | 0.008 | 331.164 | 479.924 |
| Peptides | (M+H−H2O)+ | Dopamine | 1.182 | 1.423 | 0.025 | 136.075 | 566.657 |
| Peptides | (M−H)− | D-Proline | 1.269 | 1.932 | 0.033 | 114.056 | 596.733 |
| Peptides | (M+H)+/(M−H)− | L-Alanine | 1.447 | 1.496 | 0.004 | 90.054 | 657.032 |
| Peptides | (M+H)+/(M−H)− | L-Glutamine | 1.577 | 1.6 | 0.006 | 147.075 | 710.784 |
| Peptides | (M+H)+/(M−H)− | L-Leucine | 6.368 | 1.55 | 0.002 | 132.101 | 493.523 |
| Peptides | (M+H)+ | L-Pyroglutamic acid | 1.468 | 1.483 | 0.018 | 130.049 | 710.159 |
| Peptides | (M+H)+ | L-Threonine | 1.729 | 2.082 | 0.001 | 120.064 | 670.104 |
| Peptides | (M+H)+/(M−H)− | L-Tryptophan | 2.791 | 1.879 | 0.003 | 205.096 | 483.159 |
| Peptides | (M+H)+/(M−H)− | L-Tyrosine | 2.767 | 1.437 | 0.034 | 182.081 | 566.562 |
| Peptides | (M+H)+/(M−H)− | L-Valine | 3.077 | 1.491 | 0.032 | 118.085 | 567.527 |
| Peptides | (M+NH4)+ | Methoprene (S) | 1.864 | 0.216 | 0 | 328.284 | 64.941 |
| Phenylpropanoids | (M−H)− | Cyclohexylsulfamate | 25.894 | 0.41 | 0.004 | 178.054 | 134.362 |
| Phenylpropanoids | (M+H)+ | trans-2-Hydroxycinnamic acid | 1.574 | 1.419 | 0.027 | 165.054 | 566.562 |
| Phenylpropanoids | (M−H)− | trans-cinnamate | 1.119 | 1.409 | 0.008 | 147.045 | 482.794 |
| Nucleic acids | (M−H)− | Thymine | 3.144 | 1.784 | 0.013 | 125.035 | 131.713 |
| Nucleic acids | (M+H−H2O)+ | Tyramine | 4.687 | 1.532 | 0.002 | 120.08 | 479.944 |
| Nucleic acids | (M+H)+ | Uracil | 2.953 | 1.363 | 0.04 | 113.034 | 162.164 |
| Carbohydrates | (M−H)− | D-Lyxose | 2.345 | 0.602 | 0 | 149.045 | 302.31 |
| Carbohydrates | (M+CH3COO)− | D-Ribose | 1.065 | 0.643 | 0.004 | 209.067 | 303.28 |
| Carbohydrates | (M+H−H2O)+ | N-Acetylmannosamine | 1.013 | 2.249 | 0.002 | 204.086 | 204.259 |
| Organic acids | (M−H2O−H)− | 2-Oxoadipic acid | 3.112 | 0.588 | 0.03 | 141.017 | 653.781 |
| Organic acids | (M+H)+/(M−H)− | L-Phenylalanine | 6.419 | 1.56 | 0.002 | 166.086 | 479.929 |
| Enzymes | (M−H)− | Enalapril | 1.698 | 3.048 | 0.029 | 375.184 | 335.598 |
| Terpenoids | (M+H)+ | Enoxolone | 3.645 | 5.091 | 0.029 | 471.346 | 93.061 |
| Amino acid related compounds | (M+H)+ | Capsaicin | 1.114 | 0.319 | 0.006 | 306.206 | 72.841 |
| Vitamins | (M−H)− | Nicotinate | 1.389 | 0.748 | 0.004 | 122.025 | 430.316 |
| Other | (M−H)− | 11-Keto-beta-boswellic acid | 3.341 | 11.071 | 0.024 | 469.331 | 93.427 |
| Other | (M+CH3CN+H)+ | 16-Hydroxypalmitic acid | 1.86 | 0.434 | 0 | 314.268 | 92.142 |
| Other | (M+H)+ | 1-Palmitoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine | 1.764 | 0.519 | 0.008 | 454.291 | 372.123 |
| Other | (M+H)+ | 20-Hydroxyarachidonic acid | 2.009 | 0.449 | 0.004 | 321.241 | 66.89 |
| Other | (M−H+2Na)+ | 2-Butoxyethanol | 1.051 | 0.603 | 0.047 | 163.075 | 75.237 |
| Other | (M+H)+ | 2-Deoxyinosine | 1.732 | 1.552 | 0.03 | 253.093 | 338.621 |
| Other | (M−H)− | 2-hydroxy-butanoic acid | 1.338 | 1.893 | 0.011 | 103.04 | 364.888 |
| Other | (M−H)− | 3-(3-Hydroxyphenyl) propanoic acid | 4.646 | 2.124 | 0.034 | 165.056 | 213.446 |
| Other | (M−H)− | 3,4-Dihydroxyhydrocinnamic acid | 1.291 | 2.316 | 0.048 | 181.051 | 419.406 |
| Other | (M+H−H2O)+ | DL-Indole-3-lactic acid | 2.88 | 1.762 | 0.003 | 188.07 | 482.906 |
| Other | (M+H)+/(M−H)− | DL-Methionine sulfoxide | 2.449 | 2.475 | 0 | 166.052 | 698.598 |
| Other | (M+H)+ | Erucamide | 1.216 | 0.254 | 0.025 | 338.341 | 67.109 |
| Other | (M−H)− | Gentisic acid | 1.432 | 2.331 | 0.039 | 153.019 | 135.753 |
| Other | (M+H)+ | MG(18:2(9Z,12Z)/0:0/0:0) | 3.625 | 0.398 | 0 | 355.283 | 69.542 |
| Other | (M−H)− | N-Acetyl-L-aspartic acid | 1.136 | 0.462 | 0.001 | 174.041 | 773.394 |
| Other | (M+H−H2O)+ | Phenyllactic acid | 1.026 | 1.511 | 0.002 | 149.059 | 479.928 |
| Other | (M+H)+ | Phe-Pro | 1.181 | 1.369 | 0.039 | 263.138 | 445.378 |
| Other | (M−H)− | Traumatic Acid | 1.1 | 0.298 | 0.028 | 227.129 | 576.333 |
FC, Fold change; m/z, mass-to-charge ratio; rt, retention time.
Figure 3The KEGG pathway analysis of intestinal metabolites. (A) The differential metabolites related top 20 of the enriched KEGG pathways. (B) Differential intestinal metabolites abundance analysis of KEGG pathways.
Figure 4Differential gut metabolites among 5 subgroups of HSP and healthy groups in both positive and negative ion modes. (+) shows positive ions, and (−) shows negative ions. UG, the untreated group; CON, the healthy control group; RG, the regular treated group; WG, the withdrawal group; NO-RD, no renal damage group, RD: renal damage group.
Figure 5Spearman correlation between significantly different intestinal microbes and metabolites. (A) Spearman correlation analysis network diagram of significant difference flora and significant metabolites. Red lines mean positive correlation and blue lines mean negative correlation. The darker the color, the stronger the correlation. (B) Scatter plot of AA with Agathobacter (left) and Bacteroides (right).
Figure 6Serum AA and its metabolites analysis. * means p < 0.05.